Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes.
Müssig
Karsten
K
Oncü
Arzu
A
Lindauer
Philipp
P
Heininger
Alexandra
A
Aebert
Hermann
H
Unertl
Klaus
K
Ziemer
Gerhard
G
Häring
Hans-Ulrich
HU
Holst
Jens J
JJ
Gallwitz
Baptist
B
D000368:Aged; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003327:Coronary Disease / Q000150:complications / Q000503:physiopathology* / Q000601:surgery; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage*; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D054795:Incretins / Q000008:administration & dosage*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D016896:Treatment Outcome
D001786:Blood Glucose; D054795:Incretins; D052216:Glucagon-Like Peptide 1